NATCO Pharma
Aug 25, 2016
NATCO Pharma surges; AstraZeneca falls; US patent office rules
NATCO Pharma surges 7% post successful Establishment Inspection Report for Chennai Plant NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment Inspection Report (EIR) for Chennai Plant. The U.S. Food and Drug Administration (FDA) h...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
